Details
Stereochemistry | EPIMERIC |
Molecular Formula | 2C9H13N.C4H7NO4 |
Molecular Weight | 403.5151 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC2=CC=CC=C2
InChI
InChIKey=OJNSNSZTGUACNI-VAGRMJETSA-N
InChI=1S/2C9H13N.C4H7NO4/c2*1-8(10)7-9-5-3-2-4-6-9;5-2(4(8)9)1-3(6)7/h2*2-6,8H,7,10H2,1H3;2H,1,5H2,(H,6,7)(H,8,9)/t;;2-/m..0/s1
Molecular Formula | C9H13N |
Molecular Weight | 135.2062 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H7NO4 |
Molecular Weight | 133.1027 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.caremark.com/portal/asset/FEP_Rationale_Amphetamine.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23539642
http://www.cesar.umd.edu/cesar/drugs/amphetamines.asp
Curator's Comment: description was created based on several sources, including
https://www.caremark.com/portal/asset/FEP_Rationale_Amphetamine.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23539642
http://www.cesar.umd.edu/cesar/drugs/amphetamines.asp
Amphetamine is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine was discovered in 1887 and exists as two enantiomers: levoamphetamine and dextroamphetamine. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. The drug interacts with VMAT enzymes to enhance release of DA and 5-HT from vesicles. It may also directly cause the reversal of DAT and SERT. Several currently prescribed amphetamine formulations contain both enantiomers, including Adderall, Dyanavel XR, and Evekeo, the last of which is racemic amphetamine sulfate. Amphetamine is also prescribed in enantiopure and prodrug form as dextroamphetamine and lisdexamfetamine respectively. Lisdexamfetamine is structurally different from amphetamine, and is inactive until it metabolizes into dextroamphetamine.
CNS Activity
Sources: https://nootropicscity.com/comprehensive-write-amphetamines-adderall-ritalin-vyvanse-concerta/
Curator's Comment: Amphetamines readily cross the blood-brain barrier to reach their primary sites of action in the brain. The acute administration of amphetamine produces a wide range of dose-dependent behavioral changes, including increased arousal or wakefulness, anorexia, hyperactivity, perseverative movements, and, in particular, a state of pleasurable affect, elation, and euphoria, which can lead to the abuse of the drug.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7751968 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15602501 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DYANAVEL XR Approved UseINDICATIONS Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. Attention Deficit Hyperactivity Disorder (ADHD) A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go;” excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations: Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV® characteristics. Need for Comprehensive Treatment Program: Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. Long-Term Use: The effectiveness of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Launch Date2015 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
120 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28936175/ |
40.3 mg single, oral dose: 40.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1727 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28936175/ |
40.3 mg single, oral dose: 40.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28936175/ |
40.3 mg single, oral dose: 40.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias. | 1975 |
|
The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug. | 1975 Apr 30 |
|
Atrioventricular nodal re-entrant tachycardia associated with stimulant treatment. | 1999 |
|
The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin. | 1999 Apr |
|
Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. | 1999 Apr |
|
5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. | 1999 Jun |
|
Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. | 1999 Jun 15 |
|
RU-24969 disrupts d-amphetamine self-administration and responding for conditioned reward via stimulation of 5-HT1B receptors. | 1999 Mar |
|
Changes in astrocytic basic fibroblast growth factor expression during and after prolonged exposure to escalating doses of amphetamine. | 2000 |
|
Differential regulation of calmodulin content and calmodulin messenger RNA levels by acute and repeated, intermittent amphetamine in dopaminergic terminal and midbrain areas. | 2000 |
|
Differential regional zif268 messenger RNA expression in an escalating dose/binge model of amphetamine-induced psychosis. | 2000 |
|
Regulation of the human norepinephrine transporter by cocaine and amphetamine. | 2000 Dec |
|
Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. | 2000 Jun |
|
Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. | 2000 Nov |
|
Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation. | 2001 |
|
Behavioral sensitization in humans. | 2001 |
|
[Myocardial infarction caused by amphetamine]. | 2001 Feb |
|
Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. | 2001 Jun 22 |
|
Mutant mice lacking the cholecystokinin2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine. | 2001 Jun 22 |
|
Lobeline inhibits the neurochemical and behavioral effects of amphetamine. | 2001 Mar |
|
Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. | 2001 Mar |
|
SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. | 2001 Nov |
|
Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. | 2001 Nov |
|
Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. | 2001 Nov |
|
Changes in the performance of schedule-induced polydipsia (SIP) in rats after arecoline and amphetamine treatments. | 2001 Oct |
|
Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. | 2001 Spring |
|
Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. | 2001 Summer |
|
Adderall and seizures. | 2002 Apr |
|
Synthesis and D(2)-like binding affinity of new derivatives of N-(1-ethyl-2-pyrrolidinylmethyl)-4,5-dihydro-1H-benzo[g]indole-3-carboxamide and related 4H-[1]benzothiopyrano[4,3-b]pyrrole and 5,6-dihydro-4H-benzo[6,7]cyclohepta[b]pyrrole-3-carboxamide analogues. | 2002 Aug |
|
Assessment of silver and gold substrates for the detection of amphetamine sulfate by surface enhanced Raman scattering (SERS). | 2002 Feb |
|
Effects of amphetamine on the plus-maze discriminative avoidance task in mice. | 2002 Feb |
|
Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. | 2002 Jun |
|
Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. | 2002 Jun |
|
The ability of amphetamine to evoke arc (Arg 3.1) mRNA expression in the caudate, nucleus accumbens and neocortex is modulated by environmental context. | 2002 Mar 15 |
|
Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis. | 2002 Sep |
|
Spatial and temporal profile of haloperidol-induced immediate-early gene expression and phosphoCREB binding in the dorsal and ventral striatum of amphetamine-sensitized rats. | 2002 Sep 15 |
|
Effect of amphetamine repeated treatment on the feeding behavior in neuropeptide Y-overexpressing mice. | 2002 Sep 6 |
Sample Use Guides
DYANAVEL XR (R (amphetamine) extended-release oral suspension) should be orally administered once daily in the morning with or without food. The dose should be individualized according to the needs and responses of the patient. Before administering the dose, shake the bottle of DYANAVEL XR.
In children 6 years of age and older, start with 2.5 mg or 5 mg once daily in the morning. The dose may be increase
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24672014
Curator's Comment: Amph increases the effects induced by βPEA on the LGC-55, indicating that Amph potentiates the effects generated by the biogenic amine βPEA
β-Phenylethylamine (βPEA) activates the amine-gated chloride channel LGC-55 more efficiently than amphetamine (Amph) (Km = 9 and 152 μm, respectively)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:57:15 GMT 2023
by
admin
on
Fri Dec 15 18:57:15 GMT 2023
|
Record UNII |
H527KAP6L5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
1100
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL405
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
25333-81-7
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
9801310
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
DTXSID80948178
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
H527KAP6L5
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
H527KAP6L5
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
100000086307
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
Amphetamine aspartate
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
SUB12845MIG
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
221057
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001345
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
C61636
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY | |||
|
PA 003
Created by
admin on Fri Dec 15 18:57:15 GMT 2023 , Edited by admin on Fri Dec 15 18:57:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|